Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
Purpose
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.
Conditions
- Stage II Gallbladder Cancer AJCC v8
- Stage IIA Gallbladder Cancer AJCC v8
- Stage IIB Gallbladder Cancer AJCC v8
- Stage III Gallbladder Cancer AJCC v8
- Stage IIIA Gallbladder Cancer AJCC v8
- Stage IIIB Gallbladder Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 - Patient must have histologically-confirmed T2 or T3 gallbladder cancer discovered incidentally at the time of or following routine cholecystectomy for presumed benign disease - NOTE: Patients with histologically-confirmed Tis, T1a, T1b, or T4 tumors are not eligible - Patient must have undergone initial cholecystectomy within 12 weeks prior to randomization - Patient must have the ability to understand and the willingness to sign a written informed consent document - Leukocytes >= 3,000/mcL (obtained =< 28 days prior to randomization) - Absolute neutrophil count >= 1,500/mcL (obtained =< 28 days prior to randomization) - Platelets >= 100,000/mcL (obtained =< 28 days prior to randomization) - Total bilirubin =< institutional upper limit of normal (ULN) except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome are eligible if direct bilirubin < 1.5 x ULN of the direct bilirubin (obtained =< 28 days prior to randomization) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained =< 28 days prior to randomization) - Serum creatinine =< institutional ULN OR creatinine clearance >= 50 mL/min/1.73 m^2 (Based on Cockcroft Gault estimation) (obtained =< 28 days prior to randomization) - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better
Exclusion Criteria
- Patient must not have any evidence of metastatic disease or inoperable loco-regional disease based on high-quality, preoperative, cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) of the chest, abdomen, and pelvis (C/A/P) obtained within 6 weeks prior to randomization, defined as - No radiographic evidence of distant disease (M1 disease) - No radiographic evidence of tumor invasion into multiple extrahepatic organs (T4 disease) - No radiographic evidence of distant lymph node involvement (celiac, para-aortic, para-caval lymph nodes) - No evidence of new-onset ascites - Soft tissue thickening within or in direct communication with the gallbladder fossa, peri-portal lymph node involvement, involvement of one extrahepatic organ, and other disease within the confines of what constitutes 'localized resectable' disease are allowable - Women must not be pregnant or breast feeding due to the potential harm to unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 14 days prior to randomization. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) - Women of childbearing potential and sexually active males must not expect to conceive or father children by being strongly advised to use accepted and effective method(s) of contraception or to abstain from sexual intercourse for the duration of their participation in the study
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (surgery, adjuvant therapy) |
Within 4 weeks of randomization, patients undergo surgery to remove part of the liver, the lymph nodes around the liver, and possibly the bile ducts. Patients then receive gemcitabine IV over 30 minutes and cisplatin IV over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm II (neoadjuvant therapy, surgery, adjuvant therapy) |
Patients receive gemcitabine IV over 30 minutes and cisplatin over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Approximately 4-8 weeks after completion of chemotherapy, patients whose disease has not spread to other places in the body (metastasized), then undergo surgery as in Arm I. Patients with successful surgery then resume treatment with gemcitabine IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Birmingham, Alabama 35233
Anchorage, Alaska 98508
Anchorage, Alaska 99504
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Phoenix, Arizona 85004
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Jonesboro, Arkansas 72401
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Arroyo Grande, California 93420
Burbank, California 91505
Carmichael, California 95608
Carmichael, California 95608
Elk Grove, California 95758
Los Angeles, California 90048
Site Public Contact
310-423-8965
Orange, California 92868
Palo Alto, California 94304
Rocklin, California 95765
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
San Luis Obispo, California 93401
Santa Maria, California 93444
Torrance, California 90505
Torrance, California 90509
Site Public Contact
310-517-4665
Woodland, California 95695
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80923
Denver, Colorado 80210
Durango, Colorado 81301
Durango, Colorado 81301
Lakewood, Colorado 80228
Littleton, Colorado 80122
Longmont, Colorado 80501
Parker, Colorado 80138
Pueblo, Colorado 81004
Aventura, Florida 33180
Site Public Contact
954-461-2180
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Fort Myers, Florida 33905
Gainesville, Florida 32610
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
305-243-2647
Plantation, Florida 33324
Site Public Contact
305-243-2647
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Savannah, Georgia 31404
Savannah, Georgia 31404
Boise, Idaho 83712
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83686
Twin Falls, Idaho 83301
Alton, Illinois 62002
Site Public Contact
618-463-5623
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Centralia, Illinois 62801
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60637
Decatur, Illinois 62526
Decatur, Illinois 62526
DeKalb, Illinois 60115
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Geneva, Illinois 60134
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mount Vernon, Illinois 62864
Site Public Contact
618-242-4600
New Lenox, Illinois 60451
O'Fallon, Illinois 62269
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Warrenville, Illinois 60555
Washington, Illinois 61571
Richmond, Indiana 47374
Carroll, Iowa 51401
Clive, Iowa 50325
Site Public Contact
515-241-3305
Clive, Iowa 50325
Council Bluffs, Iowa 51503
Creston, Iowa 50801
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50316
Site Public Contact
515-241-8704
Fort Dodge, Iowa 50501
Site Public Contact
515-574-8302
West Des Moines, Iowa 50266-7700
Site Public Contact
515-343-1000
West Des Moines, Iowa 50266
Garden City, Kansas 67846
Great Bend, Kansas 67530
Bardstown, Kentucky 40004
Corbin, Kentucky 40701
Lexington, Kentucky 40504
Lexington, Kentucky 40504
Lexington, Kentucky 40509
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
London, Kentucky 40741
Mount Sterling, Kentucky 40353
Lowell, Massachusetts 01854
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Brighton, Michigan 48116
Site Public Contact
800-865-1125
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49009
Kalamazoo, Michigan 49048
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Bemidji, Minnesota 56601
Thief River Falls, Minnesota 56701
Site Public Contact
605-312-3320
Worthington, Minnesota 56187
Site Public Contact
605-312-3320
Grenada, Mississippi 38901
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Ballwin, Missouri 63011
Site Public Contact
314-251-7058
Bolivar, Missouri 65613
Branson, Missouri 65616
Site Public Contact
417-269-4520
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Jefferson City, Missouri 65109
Joplin, Missouri 64804
Joplin, Missouri 64804
Rolla, Missouri 65401
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Saint Joseph, Missouri 64506
Saint Louis, Missouri 63109
Site Public Contact
314-353-1870
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Washington, Missouri 63090
Site Public Contact
636-390-1600
Missoula, Montana 59802
Kearney, Nebraska 68847
Lincoln, Nebraska 68510
Omaha, Nebraska 68122
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68131
Papillion, Nebraska 68046
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
Albany, New York 12208
Site Public Contact
518-262-5513
Commack, New York 11725
Site Public Contact
212-639-7592
Fresh Meadows, New York 11366
Site Public Contact
718-312-3446
Harrison, New York 10604
Site Public Contact
212-639-7592
Lake Success, New York 11042
Site Public Contact
516-734-8896
Manhasset, New York 11030
Site Public Contact
516-734-8896
New Hyde Park, New York 11040
Site Public Contact
516-734-8896
New York, New York 10065
Site Public Contact
212-639-7592
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Uniondale, New York 11553
Site Public Contact
212-639-7592
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Site Public Contact
701-234-6161
Fargo, North Dakota 58103
Site Public Contact
605-312-3320
Fargo, North Dakota 58104
Site Public Contact
800-437-4010
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Beavercreek, Ohio 45431
Boardman, Ohio 44512
Centerville, Ohio 45459
Centerville, Ohio 45459
Cincinnati, Ohio 45220
Cincinnati, Ohio 45236
Cincinnati, Ohio 45242
Cincinnati, Ohio 45247
Cincinnati, Ohio 45255
Columbus, Ohio 43210
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Findlay, Ohio 45840
Findlay, Ohio 45840
Findlay, Ohio 45840
Franklin, Ohio 45005-1066
Franklin, Ohio 45005
Greenville, Ohio 45331
Greenville, Ohio 45331
Kettering, Ohio 45409
Kettering, Ohio 45429
Troy, Ohio 45373
Troy, Ohio 45373
Warren, Ohio 44484
Youngstown, Ohio 44501
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Bend, Oregon 97701
Clackamas, Oregon 97015
Clackamas, Oregon 97015
Coos Bay, Oregon 97420
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Newberg, Oregon 97132
Oregon City, Oregon 97045
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97239
Redmond, Oregon 97756
Site Public Contact
541-706-2909
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Hershey, Pennsylvania 17033-0850
Philadelphia, Pennsylvania 19104
Site Public Contact
800-474-9892
Philadelphia, Pennsylvania 19107
Charleston, South Carolina 29425
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Knoxville, Tennessee 37920
Site Public Contact
865-544-9773
Memphis, Tennessee 38120
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Dallas, Texas 75235
Dallas, Texas 75390
Richardson, Texas 75080
Fairfax, Virginia 22031
Falls Church, Virginia 22042
Aberdeen, Washington 98520
Bellingham, Washington 98225
Site Public Contact
360-788-8223
Bremerton, Washington 98310
Centralia, Washington 98531
Edmonds, Washington 98026
Everett, Washington 98201
Issaquah, Washington 98029
Kennewick, Washington 99336
Lacey, Washington 98503
Longview, Washington 98632
Seattle, Washington 98101
Seattle, Washington 98107
Seattle, Washington 98122-5711
Seattle, Washington 98122
Sedro-Woolley, Washington 98284
Shelton, Washington 98584
Vancouver, Washington 98664
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Walla Walla, Washington 99362
Yelm, Washington 98597
Bridgeport, West Virginia 26330
Martinsburg, West Virginia 25401
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Eau Claire, Wisconsin 54701
La Crosse, Wisconsin 54601
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Marshfield, Wisconsin 54449
Minocqua, Wisconsin 54548
Rice Lake, Wisconsin 54868
Stevens Point, Wisconsin 54482
Weston, Wisconsin 54476
More Details
- NCT ID
- NCT04559139
- Status
- Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
Detailed Description
PRIMARY OBJECTIVE: I. To determine the difference in overall survival (OS) for patients given neoadjuvant gemcitabine hydrochloride (gemcitabine) and cisplatin prior to re-resection followed by adjuvant gemcitabine and cisplatin compared to patients who receive only adjuvant gemcitabine and cisplatin after re-resection for incidental gallbladder cancer (IGBC). SECONDARY OBJECTIVES: I. To compare the incidence of residual disease at the time of re-resection between patients with IGBC who receive perioperative chemotherapy prior to re-resection and those who receive only adjuvant chemotherapy after re-resection. II. To assess the clinical effect of preoperative chemotherapy compared to upfront re-resection on resectability among 3 cohorts: all enrolled patients, all patients who undergo staging laparoscopy, and all patients who undergo laparotomy. III. To determine the difference in progression-free survival (PFS) for patients with IGBC who receive perioperative chemotherapy prior to and after re-resection compared to patients who receive only adjuvant chemotherapy after re-resection. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Within 4 weeks of randomization, patients undergo surgery to remove part of the liver, the lymph nodes around the liver, and possibly the bile ducts. Patients then receive gemcitabine intravenously (IV) over 30 minutes and cisplatin IV over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive gemcitabine IV over 30 minutes and cisplatin over 30 minutes-24 hours on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Approximately 4-8 weeks after completion of chemotherapy, patients whose disease has not spread to other places in the body (metastasized) undergo surgery as in Arm I. Patients with successful surgery then resume treatment with gemcitabine IV and cisplatin IV on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 1 year after surgery or until disease recurrence, whichever comes first, for up to 5 years.